- Email: [email protected]
5587397 Reduction of elevated blood lactate using twice-daily dichloroacetate
PATENT ABSTRACTS
771
5587360
5587397
PLATELET ADHESION INHIBITOR
REDUCTION OF ELEVATED BLOOD LACTATE USING TWICE-DAILY DICHLOROACETATE
Sawyer Roy T Dyfed, UNITED KINGDOM Assigned to Merck Patent GmbH PCT No. PCT/GB91/01763 Sec. 371 Date Apr. 9, 1993 Sec. 102(e) Date Apr. 9, 1993 PCT Filed Oct. 10, 1991 PCT Pub. No. WO92/07005 PCT Pub. Date Apr. 30, 1992. The inhibitor is protein derived leech tissue or leech secretions (for example, from Hirudo medicinalis), which is capable of binding to native collagen, in such a way that substantially no cleavage breakdown products of coilagen molecules occur on SDS-PAGE. The protein substantially inhibits collagen-induced platelet aggregation or adhesion,has a molecular weight of 60-70 kilodaltons in reduced form and has optimum activity at pH 8.0.
Fox Anthony W Rancho La Costa, CA, UNITED STATES Assigned to Cypros Pharmaceutical Corporation This invention discloses an improved method of reducing elevated lactic acid and lactate concentrations in patients suffering from ischemic or hypoxic crises as stroke, cardiac arrest, or heart attacks, or other conditions involving surgery, that generate unwanted increases in blood or tissue lactate concentrations. This improvement comprises administering dichloroacetate (DCA), as in the sodium salt form, less than three times daily, at suitable dosages which cause the beneficial effects of DCA to persist beyond the time when the DCA has been pharmacokinetically cleared from the blood circulating in the patient.
5587456 HYDROPHOBIC ATTACHMENT SITE FOR ADHESION PEPTIDES 5587384 INHIBITORS OF POLY(ADP-RIBOSE) SYNTHETASE AND USE THEREOF TO TREAT NMDA NEUROTOXICITY Zhang Jie; Dawson Valina L; Dawson Ted M; Snyder Solomon H Baltimore, MD, UNITED STATES Assigned to The Johns Hopkins University; The United States of America lnhibitors of poly(ADP-ribose) synthetase can be used to prevent neurotoxicity mediated through N-methyl-D-aspartate (NMDA) receptors. Poly(ADP-ribose) synthetase inhibitors can be used therapeutically in the treatment of vascular stroke and neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and Huntington's disease.
Pierschbacher Michael D; Honsik Cyril J; Dreisbach Lisa B San Diego, CA, UNITED STATES Assigned to La Jolla Cancer Research Foundation The invention provides a method of attaching peptides containing a biologically active site, for example RGD-containing adhesion peptides, to a solid surface through a hydrophobic domain, and peptides so attached. The hydrophobic domain can contain either hydrophobic amino acids, such as leucine, valine, isoleucine or phenylalanine, or fatty acids, such as, for example, myristic acid, palmitic acid, arachidic acid or other fatty acids. Additionally, spacers, such as amino acids, between the hydrophobic domain and the biologically active domain can improve the presentation of the biologically active site. Specific peptides of the invention include GRGDSPASSKG4RL6RNH2; GRGDSPASSKS3RL6RNH2; and GRGDSPASS KSSKRL6RNH2.
771
5587360
5587397
PLATELET ADHESION INHIBITOR
REDUCTION OF ELEVATED BLOOD LACTATE USING TWICE-DAILY DICHLOROACETATE
Sawyer Roy T Dyfed, UNITED KINGDOM Assigned to Merck Patent GmbH PCT No. PCT/GB91/01763 Sec. 371 Date Apr. 9, 1993 Sec. 102(e) Date Apr. 9, 1993 PCT Filed Oct. 10, 1991 PCT Pub. No. WO92/07005 PCT Pub. Date Apr. 30, 1992. The inhibitor is protein derived leech tissue or leech secretions (for example, from Hirudo medicinalis), which is capable of binding to native collagen, in such a way that substantially no cleavage breakdown products of coilagen molecules occur on SDS-PAGE. The protein substantially inhibits collagen-induced platelet aggregation or adhesion,has a molecular weight of 60-70 kilodaltons in reduced form and has optimum activity at pH 8.0.
Fox Anthony W Rancho La Costa, CA, UNITED STATES Assigned to Cypros Pharmaceutical Corporation This invention discloses an improved method of reducing elevated lactic acid and lactate concentrations in patients suffering from ischemic or hypoxic crises as stroke, cardiac arrest, or heart attacks, or other conditions involving surgery, that generate unwanted increases in blood or tissue lactate concentrations. This improvement comprises administering dichloroacetate (DCA), as in the sodium salt form, less than three times daily, at suitable dosages which cause the beneficial effects of DCA to persist beyond the time when the DCA has been pharmacokinetically cleared from the blood circulating in the patient.
5587456 HYDROPHOBIC ATTACHMENT SITE FOR ADHESION PEPTIDES 5587384 INHIBITORS OF POLY(ADP-RIBOSE) SYNTHETASE AND USE THEREOF TO TREAT NMDA NEUROTOXICITY Zhang Jie; Dawson Valina L; Dawson Ted M; Snyder Solomon H Baltimore, MD, UNITED STATES Assigned to The Johns Hopkins University; The United States of America lnhibitors of poly(ADP-ribose) synthetase can be used to prevent neurotoxicity mediated through N-methyl-D-aspartate (NMDA) receptors. Poly(ADP-ribose) synthetase inhibitors can be used therapeutically in the treatment of vascular stroke and neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and Huntington's disease.
Pierschbacher Michael D; Honsik Cyril J; Dreisbach Lisa B San Diego, CA, UNITED STATES Assigned to La Jolla Cancer Research Foundation The invention provides a method of attaching peptides containing a biologically active site, for example RGD-containing adhesion peptides, to a solid surface through a hydrophobic domain, and peptides so attached. The hydrophobic domain can contain either hydrophobic amino acids, such as leucine, valine, isoleucine or phenylalanine, or fatty acids, such as, for example, myristic acid, palmitic acid, arachidic acid or other fatty acids. Additionally, spacers, such as amino acids, between the hydrophobic domain and the biologically active domain can improve the presentation of the biologically active site. Specific peptides of the invention include GRGDSPASSKG4RL6RNH2; GRGDSPASSKS3RL6RNH2; and GRGDSPASS KSSKRL6RNH2.